EpiAxis enters strategic partnership with UHN
EpiAxis Therapeutics and University Health Network (UHN) - Canada’s largest and leading research hospital - have entered into a collaboration to study a new approach to prostate cancer treatment. As part of the agreement, EpiAxis Therapeutics will supply its lead...
EpiAxis & Peptilogics enter strategic drug discovery partnership
EpiAxis Therapeutics and Peptilogics, a biotech company engineering peptide therapeutics by combining computation and biology to improve the treatment landscape for patients with life-threatening diseases, announced today that they have entered a collaboration to...
EpiAxis highlights – July 2022
July offered valuable opportunities for EpiAxis Therapeutics to update venture capitalists, corporate investors, private investors and investment bankers on its latest epigenetic findings. The company is currently working with The Sage Group to raise US$12million to...
There is currently no therapy to fight recurrent, metastatic breast cancer, which is the major source of death in women with breast cancer. Furthermore, current first-line treatments have extensive side-effects.We are determined to fix that.
Professor Sudha Rao
Founder at EpiAxis Therapeutics